nice_new_london_office_internal_3_web

NICE recommends plaque psoriasis contender for NHS use

pharmafile | August 8, 2017 | News story | Manufacturing and Production, Sales and Marketing Almirall, NICE< Skilarence, drugs, life sciences, medicine, pharma, pharmaceuticals, plaque psoriasis, psoriasis 

The use of Almirall’s psoriasis drug Skilarence (dimethyl fumarate) on the UK’s NHS is one step closer after NICE gave draft guidance recommending its use in moderate to severe plaque forms of the disease in adult patients for whom other systemic non-biological treatments are not applicable.

The institute based its decision on trial data which indicated that Skilarence was effective at improving the condition compared to placebo. However, it failed to prove as effective as existing systemic biological therapies, as well as Celgene’s drug Otzela (apremilast).

Crucially, the drug was judged as cost-effective, with a price tag of £23,115 per quality-adjusted life year.  

Advertisement

The recommendation is conditional, requiring that treatment with the drug be stopped at 16 weeks if response is not deemed adequate, as determined by a 75% reduction on the Psoriasis Area and Severity Index (PASI) since the beginning of treatment, or a 50% reduction along with a 5 point drop on the Dermatology Life Quality Index.  

Psoriasis currently affects around 950,000 people in the UK alone, and 90% of that number suffer from the plaque form of the disease.  

Matt Fellows

Related Content

Lilly opens fourth US Gateway Labs site

Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Lilly secures conditional MHRA approval for new blood cancer treatment

Crown Bioscience opens new US model development centre

Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …

The Gateway to Local Adoption Series

Latest content